December 9, 2022 8:17am

Investors should still be cautious amid choppy market action after another weak aftermarket; is it almost time for bottom fishing – we’re coming closer!

Indications:  5 Positive Indication

News: Alnylam Pharmaceuticals (ALNY +$6.68 pre-open) submitted a supplemental New Drug Application (sNDA) to the FDA for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Patisiran is the established name for ONPATTRO®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!

TGIF

8:30 a.m. edition


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are DOWN -0.16% or (-53 points), S&P futures are DOWN -0.16% or (-6 point) and NASDAQ futures are DOWN -0.19% or (-22 points) early in the pre-open – so far,

Stock futures rose slightly Friday,

European markets were up,

Asia Pacific markets rose.

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes rose Thursday as the S&P 500 cracked a losing streak and the possible high odds of a recession

  • The Dow closed UP +183.56 points (+0.55%), the S&P close UP +29.59 points (+0.75%) while the Nasdaq closed UP +123.45 points (+1.13%)

Economic Data Docket: November’s producer price index showed wholesale prices rise 0.3% last month and 7.4% over the previous year, topping the estimated 0.2% gain expected by economists polled by Dow Jones. Core PPI, which excludes food and energy, rose 0.4% last month, topping an estimate of 0.2%.

 

Thursday’s (12/8) … RegMed Investors’ (RMi) closing bell: “sector share pricing rise, not due to investors but, electronic trading and algorithms” …  https://www.regmedinvestors.com/articles/12736

 

Ebb and flow:

Q4 – December – 4 negative and 2 positive closes

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive indication:

CRISPR Therapeutics (CRSP) closed down -$0.11 to $50.50 after Thursday’s -$0.17 with a positive +$0.50 or +0.99% pre-open indication,

Intellia therapeutics (NTLA) closed up +$0.30 to $38.35 after Thursday’s -$0.93 with a positive +$0.85 or +2.22% pre-open indication,

Sage Therapeutics (SAGE) closed down -$1.16 to $39.48 after Thursday’s -$1.91 with a positive +$1.97 or +4.99% pre-open indication.

Beam Therapeutics (BEAM) closed up +$0.59 to $44.69 after Thursday’s +$0.92, Tuesday’s -$1.19 Monday’s -$2.45 and last Friday’s +$0.99, with a positive +$1.21 or +2.71% pre-open indication.

BioLife Solution (BLFS) closed up +$0.42 to $19.80 with a positive +$0.64 or +3.23% pre-open indication.

 

The BOTTOM LINE: I try to keep it simple and short!

The sector rebounded modestly on Thursday, but only regained a small portion of the losses suffered in the last several days.

Friday closes the week; the market got side stepped by inflation release!

Yet, it’s setting-up for those to bottom fish for December exits and new Year BUYS although it will be tough to get through the end-of-month sessions

“Sideways markets are among the most dangerous for investors, especially when there is volatility up and down. There's just enough strength on the upside to lure buyers in, but then the market swings lower for a time. That forces investors to either cut losses when they're small — with a good chance that stocks will rebound — or risk a much-bigger decline.” <IBD>

The current choppy market rally has an added hurdle. Most of the advance has come on a handful of one-day sessions, so it's hard to have even mini-uptrends to build gains in new positions.

In the very short term until December 31, investors may want to be cautious about making new buys. The market and sector face a big technical test with inflation and jobs reports likely to play a key role in how that plays out.

I’d be calculating selling for tax purposes.

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

Reiterating, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.